Population pharmacokinetics of tacrolimus in adult kidney transplant recipients

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 6, 2002, Pages 660-669

  Staatz, Christine E ^a   Willis, Charlene ^a   Taylor, Paul J ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOAVAILABILITY; BLOOD SAMPLING; CREATININE CLEARANCE; DRUG EFFECT; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOCRIT; HUMAN; KIDNEY TRANSPLANTATION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; POPULATION RESEARCH; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; BAYES THEOREM; CHROMATOGRAPHY, LIQUID; CREATININE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HEMATOCRIT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER FUNCTION TESTS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 0036913473     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.129304     Document Type: Article

References (41)

1. Plosker GL, Foster RH. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000;59:323-89.
2. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-30.
3. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, et al. Consensus document: Therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 1995;17:606-14.
4. Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999;39:995-1005.
5. Lee CC, Hewitt JM, Aweeka FT, Canafax DM, Vincenti D, Tworek D, et al. Pharmacokinetics of tacrolimus (FK506) prior to kidney transplantation [abstract]. Clin Pharmacol Ther 1993;53:238.
6. Japanese FK506 Study Group. Japanese study of FK506 on kidney transplantation: The benefit of monitoring whole blood FK506 concentrations in patients. Transplant Proc 1991;23:3085-8.
7. Aweeka FT, Benet LZ, Gambertoglio JG, Peter K, Okudaira N, Kinda J, et al. Comparative pharmacokinetics of orally (PO) and intravenously (IV) administered tacrolimus (FK506) in pre- and post-kidney transplant recipients [abstract]. Clin Pharmacol Ther 1993;53:151.
8. Mekki QA, Lee CC, Aweeka FT, Laskow DA, Neylan JF, Mendez R, et al. Pharmacokinetics of tacrolimus (FK506) in kidney transplant patients [abstract]. Clin Pharmacol Ther 1993;53:238.
9. Gruber SA, Hewitt JM, Sorenson AL, Barber DL, Bowers L, Rynders G, et al. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol 1994;34:859-64.
10. Taylor PJ, Jones A, Balderson GA, Lynch SV, Norris RL, Pond SM. Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 1996;42:279-85.
11. van Hooff JP, Boots JM, van Duijnhoven EM, Christiaans MH. Dosing and management guidelines for tacrolimus in renal transplant patients. Transplant Proc 1999;31:54S-7S.
12. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 1992;22:447-67.
13. Tett SE, Holford NHG, McLachlan AJ. Population pharmacokinetics and pharmacodynamics: An underutilized resource. Drug Info J 1998;32:693-710.
14. Taylor PJ, Hogan NS, Lynch SV, Johnson AG, Pond SM. Improved therapeutic drug monitoring of tacrolimus (FK506) by tandem mass spectrometry. Clin Chem 1997;43:2189-90.
15. Beal SL, Sheiner LB, editors. NONMEM User's Guide. San Francisco: NONMEM Project Group, University of California; 1992.
16. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995;57:281-90.
17. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf 1997;16:267-78.
18. Matsuda H, Iwasaki K, Shiraga T, Tozuka Z, Hata T, Guengerich FP. Interactions of FK506 (tacrolimus) with clinically important drugs. Res Commun Mol Pathol Pharmacol 1996;91:57-64.
19. Iwasaki K, Matsuda H, Nagase K, Shiraga T, Tokuma Y, Uchida K. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993;82:209-16.
20. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc 1998;30:1261-3.
21. Beysens AJ, Wijnen RMH, Beuman GH, van der Heyden J, Kootstra G, van As H. FK506: Monitoring in plasma or in whole blood? Transplant Proc 1991;23:2745-7.
22. Huang ML, Venkataramanan R, Burckart GJ, Ptachcinski RJ, Van Thiel DH, Starzl TE. Drug binding in liver transplant patients. J Clin Pharmacol 1998;28:505-6.
23. Jain AB, Venkataramanan R, Cadoff E, Fung JJ, Todo S, Krajack A, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990;22:57-9.
24. Abu-Elmagd K, Fung JJ, Alessiani M, Jain A, Venkataramanan R, Warty VS, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991;52:71-7.
25. Moss D. Liver function tests. Medicine International 1994;22:425-31.
26. Fitzsimmons WE, Bekersky I, Dressier D, Rayne K, Hodosh E, Mekki Q. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 1998;30:1359-64.
27. al-Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm 1990;18:347-60.
28. Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 1991;19:333-53.
29. Jonsson EN, Wade JR, Karlsson MO. Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm 1996;24:245-63.
30. Wade JR, Kelman AW, Howie CA, Whiting B. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinetic Biopharm 1993;21:209-22.
31. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. 3. Monoexponential model: Routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983;11:303-19.
32. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation 1994;57:519-25.
33. Staatz CE, Taylor PJ, Lynch SV, Willis C, Charles BG, Tett SE. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 2001;72:1056-61.
34. Rui JZ, Zhuo HT, Jiang GH, Chen G. Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM [in Chinese]. Yao Xue Xue Bao 1995;30:241-7.
35. Parke J, Charles BG. NONMEM population pharmacokinetic modelling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. Ther Drug Monit 1998;20:284-93.
36. Yasuhara M, Hashida T, Toraguchi M, Hashimoto Y, Kimura M, Inui K, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 1995;27:1108-10.
37. Garcia Sanchez MJ, Manzanares C, Santos-Buelga D, Blazquez A, Manzanares J, Urruzuno P, et al. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 2001;40:63-71.
38. Sam WJ, Aw M, Quak SH, Lim SM, Charles BG, Chan SY, et al. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 2000;50:531-41.
39. Kahan BD. High variability of drug exposure: A biopharmaceutic risk factor for chronic rejection. Transplant Proc 1998;30:1639-41.
40. Lown KS, Mayo RR. Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
41. Aarons L, Balant LP, Mentre F, Morselli PL, Rowland M, Steimer JL, et al. Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur J Clin Pharmacol 1994;46:389-91.